Eight patients with FGFR1-amplified breast cancer and 9 with FGFR2-amplified gastroesophageal cancer were treated with AZD4547 in a translational clinical trial (Supplementary Fig. S1A). One FGFR1-amplified (12.5% response rate) and 3 FGFR2-amplified (33% response rate) patients had confirmed responses to AZD4547 (Fig. 1A and B), reaching the predefined criteria for efficacy in the FGFR2-amplified cohort.